We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+4.37%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$352M
AUM Growth
-$102M
(-22%)
Cap. Flow
-$110M
Cap. Flow
% of AUM
-31.19%
Top 10 Holdings %
Top 10 Hldgs %
95.26%
Holding
17
New
2
Increased
4
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$10.4M |
| 2 |
Pacira BioSciences
PCRX
|
+$5.94M |
| 3 |
ADXS
Advaxis Inc
ADXS
|
+$5.12M |
| 4 |
ARRY
Array Biopharma Inc
ARRY
|
+$4.64M |
| 5 |
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
|
+$769K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$93.2M |
| 2 |
Quest Diagnostics
DGX
|
+$31.7M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$10.7M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
+$970K |
| 5 |
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
|
+$303K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $95M | 26.95% |
12,850,000
| – | – |
|
2
Biogen
BIIB
$30B
| $75M | 21.28% |
310,000
| – | – |
|
|
MDCO
3
DELISTED
Medicines Co
MDCO
| $58.9M | 16.72% |
1,752,000
| – | – |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $26.2M | 7.44% |
675,000
| – | – |
|
|
5
Pacira BioSciences
PCRX
$1.04B
| $22M | 6.25% |
653,000
+120,800
| +23% | +$5.94M |
|
|
RPTP
6
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $15.4M | 4.38% |
2,875,000
+150,000
| +6% | +$769K |
|
|
ARRY
7
DELISTED
Array Biopharma Inc
ARRY
| $15.3M | 4.35% |
4,300,000
+1,425,000
| +50% | +$4.64M |
|
|
8
Quest Diagnostics
DGX
$25.7B
| $12.9M | 3.67% |
159,000
-416,000
| -72% | -$31.7M |
|
|
9
Perrigo
PRGO
$1.4B
| $9.07M | 2.57% |
+100,000
| New | +$10.4M |
|
|
SEEL
10
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $5.78M | 1.64% |
13
| – | – |
|
|
ADXS
11
DELISTED
Advaxis Inc
ADXS
| $4.85M | 1.38% |
+40,000
| New | +$5.12M |
|
|
AEGR
12
DELISTED
Aegerion Pharmaceuticals
AEGR
| $3.95M | 1.12% |
2,649,000
+69,000
| +3% | +$158K |
|
|
13
AbbVie
ABBV
$443B
| $3.1M | 0.88% |
50,000
-1,530,000
| -97% | -$93.2M |
|
|
VVUS
14
DELISTED
Vivus Inc
VVUS
| $2.88M | 0.82% |
257,394
| – | – |
|
|
AVEO
15
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $1.92M | 0.55% |
200,000
-31,376
| -14% | -$303K |
|
|
ESPR
16
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-633,000
| Closed | -$10.7M |
|
|
RPRX
17
DELISTED
Repros Therapeutics Inc.
RPRX
| – | – |
-1,001,000
| Closed | -$970K |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Sarissa Capital Management held 17 positions worth $352M, down 22% from $454M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Sarissa Capital Management withdrew a net $110M in Q2 2016, closing 2 positions and reducing 3 holdings. Its most notable exit was Esperion Therapeutics, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 85% a quarter earlier.
Against the trend, Sarissa Capital Management opened a new position in Perrigo worth $9.07M.
- Sarissa Capital Management's largest Q2 2016 buy was Perrigo: 100,000 shares worth $9.07M.
- Sarissa Capital Management added most to Pacira BioSciences in Q2 2016, an estimated $5.94M increase.
- Sarissa Capital Management's biggest Q2 2016 reduction was AbbVie, cutting an estimated $93.2M.
- Sarissa Capital Management fully exited Esperion Therapeutics in Q2 2016, selling an estimated $10.7M.
- Sarissa Capital Management's ten largest holdings make up 95% of its $352M portfolio in Q2 2016.
- Sarissa Capital Management opened 2 new positions and closed 2 in Q2 2016.
- Sarissa Capital Management's portfolio value fell 22% quarter-over-quarter to $352M.
Based on Sarissa Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.